Skip to main content
TSX Real-Time Last Sale CAD
Today's Change
Volume
Price Quote as of

More stories below advertisement

Latest Press Releases

Organigram CEO Joins Canadian Chamber of Commerce Board of Directors
- BusinessWire - Fri Oct 30, 2:00AM CDT
BusinessWire - CMTX
Fri Oct 30, 2:00AM CDT
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (the "Company" or "Organigram"), a leading licensed producer of cannabis, is pleased to announce that the Company's Chief Executive Officer, Greg Engel, has accepted a position on the Board of Directors of the Canadian Chamber of Commerce.
Hyasynth completes key commercialization milestone for cannabinoid biosynthesis, receives $2.5 million payment
- CNW Group - Fri Oct 23, 9:22AM CDT
CNW Group - CMTX
Fri Oct 23, 9:22AM CDT
Hyasynth completes key commercialization milestone for cannabinoid biosynthesis, receives $2.5 million payment
Organigram Confirms Additional $2.5 Million Investment in Hyasynth Biologicals Inc. as Biosynthesis Pioneer Completes First Milestone Linked to First Sale of Commercial Product and Announces Executive Changes
- BusinessWire - Fri Oct 23, 5:00AM CDT
BusinessWire - CMTX
Fri Oct 23, 5:00AM CDT
As an early investor in biosynthesis, Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (the "Company" or "Organigram"), a leading licensed producer of cannabis, is pleased to announce it has funded an additional $2.5 million investment in Hyasynth Biologicals Inc. ("Hyasynth"), a private biotechnology company and pioneer in the field of cannabinoid science and biosynthesis. The announcement comes as Hyasynth makes the first sale of CBDa(1) produced and extracted from yeast.
Regulatory Landscape for CBD Medical Grade Products Targeting New Safety Levels for Consumers
- PR Newswire - PRF - Wed Sep 30, 7:45AM CDT
PR Newswire - PRF - CMTX
Wed Sep 30, 7:45AM CDT
, /PRNewswire/ -- Medical grade CBD products market is poised for significant increase in revenues for the next several years. It seems that every new industry report has higher projections that the earlier reports. Data Bridge Markets Research itself has proffered some of these reports. One such said that the CBD oil extract market is expected to gain market growth in the forecast period of 2020 to 2027 projecting that the market will rise to by 2027 growing at a CAGR of 21.0% in the above-mentioned forecast period. It stated that the growing awareness amongst the patients regarding the benefits of CBD oil will help in driving the growth of the market. Another report from Data Bridge addressing the global CBD oil market itself, said that CBD oil market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 38.4% in the forecast period of 2020 to 2027 and expected to reach by 2027.   Mentioned in today's commentary include:  (NASDAQ: TLRY), (OTCPK: RTSL), (NASDAQ: CRON) (TSX: CRON), (NASDAQ: OGI) (TSX: OGI), (TSX: AH) (OTCQX: ALEAF).
Organigram Expands Strong Value Portfolio With Launch of SHRED: High Quality, High Potency, Affordable Pre-shredded Dried Flower
- BusinessWire - Thu Sep 17, 5:00AM CDT
BusinessWire - CMTX
Thu Sep 17, 5:00AM CDT
In an effort to continue to break down the barriers to purchasing from the legal cannabis market in Canada, and reinforce its ongoing commitment to value, Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (the "Company" or "Organigram"), a leading licensed producer of cannabis, is pleased to announce the launch of SHRED, a high quality, high potency, affordable dried flower product pre-shredded for additional consumer convenience.
Organigram Joins Medical Cannabis by Shoppers Inc. and TruTrace in Effort to Track Source and Genetics of Cannabis Used by Medical Patients
- BusinessWire - Tue Aug 18, 5:00AM CDT
BusinessWire - CMTX
Tue Aug 18, 5:00AM CDT
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (the "Company" or "Organigram"), a leading licensed producer of cannabis, is pleased to announce it has partnered with Medical Cannabis by Shoppers(TM)("Shoppers") on Phase 2 of Shoppers' Pilot Program powered by software partner TruTrace Technologies Inc. (CSE: TTT; OTCQB: TTTSF) ("TruTrace").
Organigram Sends First Shipment of Indoor-Grown Dried Flower to Israeli Cannabis Producer, Canndoc Ltd.
- BusinessWire - Fri Aug 14, 5:00AM CDT
BusinessWire - CMTX
Fri Aug 14, 5:00AM CDT
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (the "Company" or "Organigram"), a leading licensed producer of cannabis, today announced that it has sent its first shipment of bulk dried flower to Canndoc Ltd. ("Canndoc"), one of Israel's largest and most established medical cannabis producers, and a subsidiary of InterCure Ltd. (TASE: INCR). The shipment is part of Organigram's multi-year deal with Canndoc and is estimated to be worth approximately $2.4M CDN.
Organigram Strengthens Edison Flower Portfolio with Three New High Potency Strains - The General (Grapefruit GG4), Chemdog and Samurai Spy (Ninja Fruit)
- BusinessWire - Tue Aug 4, 5:00AM CDT
BusinessWire - CMTX
Tue Aug 4, 5:00AM CDT
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (the "Company" or "Organigram"), a leading licensed producer of cannabis, is pleased to announce the launch of three new strains of Edison Cannabis Co. ("Edison") dried flower products, including higher tetrahydrocannabinol (THC) options The General (Grapefruit GG4), Chemdog and limited time option Samurai Spy (Ninja Fruit).
Billion Dollar CBD Market Revenue Projected to Climb as Sales Increase
- MENAFN - Wed Jun 24, 10:03PM CDT
MENAFN - CMTX
Wed Jun 24, 10:03PM CDT
Palm Beach, FL - June 24, 2020 - Of the more than 85 cannabinoids so far identified in the cannabis plant, CBD is the second most common after tetrahydrocannabinol (THC) but is in the news more and more every day. Global Market Insights, Inc. has recently added a new report on cannabidiol (CBD) market which estimates the global market valuation for cannabidiol will cross US$ 89 billion by 2026. Growing medical applications and increasing sales of cannabidiol derived products in retail stores are two major factors supplementing the market growth. The report said: ''After passing the Farm Bill in 2018, there has been a significant demand for CBD products across the globe especially in developed countries such as the U.S., France, Canada and Netherlands among others. The sales of CBD products are also increasing rapidly as cannabidiol-based products contain trace amounts of THC (psychoactive compound) and varied amounts of CBD. Also, many cannabidiol product manufacturing companies have partnered with big retail stores across countries which is expected to double the sales... According to this GMI report, the neurological conditions application segment is projected to grow with a considerable CAGR of 51.8% during the forecast timeframe. Cannabidiol has been proven to reduce the seizures and nausea associated with few of the neurological conditions such as Parkinson''s disease, Alzheimer''s disease, epilepsy and others. There around 5.5 million individuals in the U.S. suffering from Alzheimer''s disease and around 1.2% of the total U.S. population suffers from epilepsy. Such increasing incidences of neurological disorders will aid in augmenting the CBD market growth.'' Active companies in the Cannabis market this week include (OTCQB: NUGS), (NYSE: ACB) (TSX: ACB), . (NASDAQ: OGI) (TSX: OGI), (OTCPK: MJNA), (OTCPK: PURA).
Billion Dollar CBD Market Revenue Projected to Climb as Sales Increase
- PR Newswire - PRF - Wed Jun 24, 7:55AM CDT
PR Newswire - PRF - CMTX
Wed Jun 24, 7:55AM CDT
, /PRNewswire/ -- Of the more than 85 cannabinoids so far identified in the cannabis plant, CBD is the second most common after tetrahydrocannabinol (THC) but is in the news more and more every day. Global Market Insights, Inc. has on cannabidiol (CBD) market which estimates the global market valuation for cannabidiol will cross by 2026. Growing medical applications and increasing sales of cannabidiol derived products in retail stores are two major factors supplementing the market growth. The report said: "After passing the Farm Bill in 2018, there has been a significant demand for CBD products across the globe especially in developed countries such as the U.S., , and among others. The sales of CBD products are also increasing rapidly as cannabidiol-based products contain trace amounts of THC (psychoactive compound) and varied amounts of CBD. Also, many cannabidiol product manufacturing companies have partnered with big retail stores across countries which is expected to double the sales… According to this GMI report, the neurological conditions application segment is projected to grow with a considerable CAGR of 51.8% during the forecast timeframe. Cannabidiol has been proven to reduce the seizures and nausea associated with few of the neurological conditions such as Parkinson's disease, Alzheimer's disease, epilepsy and others. There around 5.5 million individuals in the U.S. suffering from Alzheimer's disease and around 1.2% of the total U.S. population suffers from epilepsy. Such increasing incidences of neurological disorders will aid in augmenting the CBD market growth."  Active companies in the Cannabis market this week include (OTCQB: NUGS), (NYSE: ACB) (TSX: ACB), . (NASDAQ: OGI) (TSX: OGI), (OTCPK: MJNA), (OTCPK: PURA).

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2020.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies